NCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
1 trialsPhase 2 × Malignant Female Reproductive System Neoplasm × Magnetic Resonance Spectroscopy × Clear all